Treatment
Combination therapy clinical trials
We’re tracking 888 recruiting studies that include Combination therapy, each written for real people, not researchers, below.
Recruiting studies
- NCT06423885RecruitingPhase 2
Study of BL-M07D1 combination for advanced HER2-positive stomach cancer
This study tests a new combination therapy (BL-M07D1 plus another drug) for people with advanced HER2-positive stomach or gastroesophageal junction cancer. It aims to see if the combination can shrink tumors or slow cancer growth.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07340398RecruitingPhase 2
Testing new drug combos for HER2-positive breast cancer not responding to first therapy
This trial tests a new combination of drugs for people with HER2-positive early breast cancer whose tumors did not respond well to the first round of standard targeted therapy plus chemo. The goal is to see if switching to trastuzumab-rezetecan plus pertuzumab or a different chemo combo (nab-paclitaxel, carboplatin, trastuzumab, and pyrotinib) can shrink the tumor before surgery.
HangzhouAges 18–75 - NCT07111520RecruitingPhase 1/Phase 2
Combination treatment for advanced lung cancer
This trial tests two investigational drugs, BNT326 and BNT327, together in people with advanced non-small cell lung cancer (NSCLC) that has spread or can't be cured with local treatment. The goal is to see if the combination is safe and might help shrink tumors.
Los Angeles, CaliforniaAges 18 years+ - NCT07154745RecruitingPhase 3
New combination therapy for PNH when current treatment isn't working
This trial tests a new combination of two drugs (pozelimab and cemdisiran) for adults with PNH whose current treatment (eculizumab, ravulizumab, or crovalimab) isn't controlling their symptoms well. It aims to see if the combination reduces red blood cell breakdown and improves blood counts.
Ribeirão Preto, São PauloAges 18 years+ - NCT06128551RecruitingPhase 1/Phase 2
Testing two targeted drugs for KRAS G12C advanced cancer
This study tests two oral medicines (elironrasib and daraxonrasib) given alone or together to see if they can shrink tumors or slow down cancer growth in people with advanced solid tumors that have a KRAS G12C mutation. It is for people who have already tried other treatments.
Duarte, CaliforniaAges 18 years+ - NCT07227025RecruitingPhase 1/Phase 2
Study of amivantamab and olomorasib for KRAS G12C lung cancer
This trial tests a new combination of two targeted drugs (amivantamab and olomorasib) for people with advanced lung cancer that has a specific KRAS G12C mutation. It's for those whose cancer has grown despite prior chemotherapy and immunotherapy.
New York, New YorkAges 18 years+ - NCT05744921RecruitingPhase 3
Pozelizumab plus cemdisiran for adult PNH over the long term
This Phase 3 study tests whether long-term treatment with pozeli(z)umab plus cemdisiran is safe and works well in adults with paroxysmal nocturnal hemoglobinuria (PNH). It is mainly for people whose PNH does not respond to certain standard medicines or who have genetic changes that make them refractory.
Toronto, OntarioAges 18 years+ - NCT06622057RecruitingPhase 3
D07001 and capecitabine for advanced bile duct cancer
This trial tests a combination of two oral medications, D07001 and capecitabine, for people with advanced bile duct, gallbladder, or ampullary cancer that has gotten worse after standard chemotherapy. The goal is to see if this combination can help control the cancer.
Tucson, ArizonaAges 18 years+ - NCT07479485RecruitingPhase 1/Phase 2
MRG006A combo for advanced liver cancer
This trial tests a new drug combination called MRG006A for people with advanced liver cancer (hepatocellular carcinoma) that cannot be removed by surgery or treated with local therapies. The goal is to see if it helps shrink tumors or slow cancer growth.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06445972RecruitingPhase 1/Phase 2
Testing combination therapies for advanced stomach or esophageal cancer
This study tests new drug combinations for people with advanced stomach or esophageal cancer that worsened after first treatment. It aims to find better options for those whose tumors lack HER2.
Tucson, ArizonaAges 18 years+ - NCT07722884Recruiting
Tamsulosin alone or with tadalafil for enlarged prostate symptoms
This study tests whether taking tadalafil (at 2.5 mg or 5 mg) along with tamsulosin is better for treating urinary symptoms caused by an enlarged prostate than taking tamsulosin alone. It aims to find the best dose combination to improve your quality of life.
Cairo, Cairo GovernorateAges 45 years+ - NCT05797168RecruitingPhase 1/Phase 2
Early study drug for advanced solid tumors, alone or with another drug
This Phase 1/2 study tests a new AstraZeneca cancer drug (AZD5335) to see how safely it can be given and how well it works in people with advanced solid tumors. You may get it alone or with another treatment, and you’ll need to provide tumor information (sometimes including a biopsy) for study planning.
Duarte, CaliforniaAges 18–130 - NCT07325136RecruitingPhase 1/Phase 2
BMS-986525 for Relapsed Small Cell Lung Cancer
This study tests a new drug called BMS-986525, alone or with other treatments, for people with small cell lung cancer that has come back or not responded to treatment. It aims to find out if the drug is safe and tolerable.
Detroit, MichiganAges 18 years+ - NCT06892548RecruitingPhase 1/Phase 2
Combination therapy for advanced lung cancer
This trial tests a new combination of two investigational drugs, BNT324 and BNT327, for people with advanced lung cancer that cannot be removed by surgery. It aims to see if the combination is safe and effective for different types of lung cancer, including non-small cell and small cell lung cancer.
Phoenix, ArizonaAges 18 years+ - NCT07010497RecruitingPhase 2
Study of a three-drug combo for advanced liver cancer
This trial tests a new combination of three drugs (Irpagratinib, Atezolizumab, and Bevacizumab) for people with advanced liver cancer that cannot be removed by surgery. It aims to see if this combination is safe and effective.
SeoulAges 19 years+ - NCT03498326RecruitingPhase 2
Gemcitabine plus celecoxib after pancreatic surgery
This trial tests whether adding celecoxib to gemcitabine chemotherapy after complete (R0) pancreatic tumor removal can lower the chance the cancer comes back. It may help people who have had successful surgery but still need anti-cancer treatment.
Hangzhou, ZhejiangAges 18–90 - NCT03821246RecruitingPhase 2
Atezolizumab and other drugs before prostate surgery for high-risk cancer
This Phase 2 trial tests whether giving immunotherapy (atezolizumab) plus another drug before surgery can shrink or control high-risk localized prostate cancer. The goal is to improve outcomes by treating the cancer early, before radical prostatectomy.
San Francisco, CaliforniaAges 18 years+ - NCT03844061RecruitingPhase 2
Belimumab plus rituximab for early diffuse scleroderma skin disease
This Phase 2 study tests whether combining belimumab and rituximab can improve skin thickening in people with early diffuse cutaneous systemic sclerosis (dcSSc). It may help slow the disease process and improve skin symptoms, but it also requires screening for immune and infection risks.
New York, New YorkAges 18–80 - NCT04429542RecruitingPhase 1
Test of an EGFR-targeting drug for advanced solid cancers
This Phase 1 study tests the safety of BCA101 (an EGFR-targeting treatment) alone or combined with pembrolizumab. It may help people with certain EGFR-driven advanced cancers, depending on the tumor type, prior treatments, and required biopsy testing.
La Jolla, CaliforniaAges 18 years+ - NCT04494503RecruitingPhase 1/Phase 2
Study drug for hard-to-treat CLL or SLL after relapse
This Phase 1/2 study tests APG2575 alone or combined with other treatment in people whose CLL/SLL has come back or did not respond to prior therapy. The goal is to see how well the treatment works and how safe it is.
Beijing, Beijing MunicipalityAges 18 years+ - NCT04510597RecruitingPhase 3
Immunotherapy plus surgery versus immunotherapy alone for kidney cancer
This study tests whether adding surgery to remove the kidney improves outcomes compared with continuing immunotherapy without surgery. It is for people with metastatic kidney cancer whose disease has not worsened after initial immunotherapy.
Birmingham, AlabamaAges 18 years+ - NCT04566328RecruitingPhase 3
Newly diagnosed multiple myeloma test of combination therapy
This Phase 3 trial tests a combination treatment approach for adults with newly diagnosed multiple myeloma, focusing on response and deeper remission. It may help by improving how well the disease is controlled early and measuring results beyond standard tests.
Anchorage, AlaskaAges 18 years+ - NCT04578652RecruitingPhase 3
Test fiber plus metformin for teen weight and insulin resistance
This trial studies whether adding fiber to metformin helps teens with severe obesity and insulin resistance improve how their bodies handle sugar. You might consider it if you’re a teen who isn’t yet diagnosed with type 2 diabetes and meets the specific lab and health criteria.
Edmonton, AlbertaAges 12–18 - NCT04895709RecruitingPhase 1/Phase 2
Testing a new cancer drug for advanced solid tumors
This early-phase trial tests how well a new drug (BMS-986340) works alone and combined with other treatments in people with advanced solid tumors that have progressed despite standard care. It also studies tumor samples to look for biomarkers that may predict who benefits.
Clovis, CaliforniaAges 18 years+
Common questions
- Are there clinical trials studying Combination therapy?
- Yes. Clin2 currently lists 888 recruiting studies that include Combination therapy, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Combination therapy trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Combination therapy an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Combination therapy or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.